- Anniversary/History
- Membership
- Publications
- Resources
- Education
- Events
- Outreach
- Careers
- About
- For Pain Patients and Professionals
The mechanisms underlying inter-individual variability in analgesic efficacy of non-steroidal anti-inflammatory drugs are not well understood. Therefore, we performed pain phenotyping, functional neuroimaging, pharmacokinetic/pharmacodynamic assessments, inflammation biomarkers, and gene expression profiling in healthy subjects who underwent surgical extraction of bony impacted third molars and were treated with ibuprofen (400 mg; N=19) or placebo (N=10). Analgesic efficacy was not associated with demographic or clinical characteristics, ibuprofen pharmacokinetics, or the degree of cyclooxygenase inhibition by ibuprofen. Compared to partial responders to ibuprofen (N=9, required rescue medication within the dosing interval), complete responders (N=10, no rescue medication) exhibited greater induction of urinary prostaglandin metabolites and serum tumor necrosis factor-α and interleukin-8. Differentially expressed genes in peripheral blood mononuclear cells were enriched for inflammation-related pathways. These findings suggest that a less pronounced activation of the inflammatory prostanoid system is associated with insufficient pain relief on ibuprofen alone and the need for additional therapeutic intervention. This article is protected by copyright. All rights reserved.